As an important agent of Aβ protein clearance through the blood–brain barrier, low-density lipoprotein receptor-related protein 1(LRP1) may be used as a therapeutic target for regulating the pathological changes of cognitive disorders (Sparks et al., 2006; Storck and Pietrzik, 2017). The gene discussed is LRP1; the disease is Cognitive impairment.